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Tumor cells exhibit two different modes of individual
cell movement. Mesenchymal-type movement is
characterized by an elongated cellular morphology
and requires extracellular proteolysis. In amoeboid
movement, cells have a rounded morphology, are
less dependent on proteases, and require high
Rho-kinase signaling to drive elevated levels of acto-
myosin contractility. These two modes of cell move-
ment are interconvertible. We show that mesenchy-
mal-type movement in melanoma cells is driven by
activation of the GTPase Rac through a complex
containing NEDD9, a recently identified melanoma
metastasis gene, and DOCK3, a Rac guanine nucleo-
tide exchange factor. Rac signals through WAVE2 to
direct mesenchymal movement and suppress amoe-
boid movement through decreasing actomyosin
contractility. Conversely, in amoeboid movement,
Rho-kinase signaling activates a Rac GAP, ARH-
GAP22, that suppresses mesenchymal movement
by inactivating Rac. We demonstrate tight interplay
between Rho and Rac in determining different
modes of tumor cell movement, revealing how tumor
cells switch between different modes of movement.
INTRODUCTION
Abnormal cell migration and invasion is a characteristic of malig-
nant cancer cells and is one component of metastasis, the major
clinical problem in cancer. To metastasize, tumor cells must
move through tissues and cross tissue boundaries, which re-
quires cell motility, remodeling of cell-cell contacts, and interac-
tions with the extracellular matrix (Fidler, 1999). Tumor cells can
move as individual cells or as collective groups (Wolf et al., 2007).
Recent work has demonstrated that individual tumor cells have
two different modes of movement: a mesenchymal mode char-
acterized by an elongated morphology that requires extracellular
proteolysis localized at cellular protrusions and an amoeboid510 Cell 135, 510–523, October 31, 2008 ª2008 Elsevier Inc.mode in which movement is independent of proteases and cells
have a rounded morphology with no obvious polarity (Wolf et al.,
2003). In amoeboid movement, the cell surface undergoes very
active blebbing driven by actomyosin contractility (Sahai and
Marshall, 2003; Wyckoff et al., 2006). It is also clear that these
two modes of tumor cell movement are interconvertible, de-
pending on environmental conditions (De Wever et al., 2004;
Wolf et al., 2003). Consequently, the ability of tumor cells to
switch between different modes of motility may limit the effec-
tiveness of single therapeutic agents aimed at reducing invasion.
Members of the Rho family of small GTPases are key regula-
tors of cell movement through their actions on actin assembly,
actomyosin contractility, and microtubules (Ridley, 2001). Ex-
pression of Rho family proteins is deregulated in some tumors
and correlates with progression of disease (Sahai and Marshall,
2002). The three prototypical members of the family, Rho, Rac,
and Cdc42, have all been linked to cell movement. Rac1 drives
motility by promoting lamellipodia formation (Ridley et al.,
1992), whereas RhoA signals to the kinases ROCKI and II, pro-
moting the formation of actin stress fibers and generation of
the actomyosin contractile force required for cell movement
(Amano et al., 1997; Kimura et al., 1996). Previous work shows
that amoeboid and mesenchymal modes of movement are dis-
tinguished by their different usage of signaling pathways. The
amoeboid mode involves signaling through ROCK, whereas
the mesenchymal mode does not have an obligate requirement
for ROCK but requires extracellular proteolysis (Sahai and Mar-
shall, 2003) for Rac-dependent actin protrusions to be pushed
through channels in the extracellular matrix (Wolf et al., 2003).
Amoeboid movement is characterized by high levels of actomy-
osin contractility driven by ROCK (Wilkinson et al., 2005), consis-
tent with a mechanism whereby cells squeeze through voids and
deform the matrix (Wolf et al., 2003; Wyckoff et al., 2006).
To investigate mechanisms of different modes of cell move-
ment, we have studied how the regulation of Rho family GTPases
determines the mode of tumor cell movement. Guanine nucleo-
tide exchange factors (GEFs) and GTPase accelerating proteins
(GAPs) are key regulators of small GTPases, with GEFs promot-
ing activation to the GTP bound state and GAPs promoting inac-
tivation by stimulating GTP hydrolysis (Bos et al., 2007). We car-
ried out a systematic siRNA screen of GEFs and GAPs to identify
regulators of Rho family GTPases affecting modes of tumor cell
movement. We show that a Rac-specific GEF, DOCK3, in asso-
ciation with the adaptor molecule NEDD9, regulates Rac and
WAVE2 to drive mesenchymal movement and suppress amoe-
boid movement. Conversely, in amoeboid movement, Rho sig-
naling via ROCK to a Rac GAP, ARHGAP22, inactivates Rac
and suppresses mesenchymal movement.
RESULTS
DOCK3 Is a Rac GEF Regulating the Transition between
Amoeboid and Mesenchymal Movement
To investigate Rho family GTPase signaling pathways involved in
tumor cell morphology and movement, we initially used A375M2
melanoma cells that show amoeboid movement in vivo (Pinner
and Sahai, 2008) and in 3D tissue culture (Sahai and Marshall,
2003; Wilkinson et al., 2005). Cells were plated on top of a thick
deformable layer of collagen I, and cell morphology and move-
Figure 1. DOCK3 Is Required for the Amoe-
boid-Mesenchymal Transition
(A) Upper panel: images of Mock or DOCK3
siRNA-transfected A375M2 cells plated on a thick
layer of collagen for 24 hr. The scale bar repre-
sents 100 mm. Lower panel: DOCK3 immunoblot.
(B) Upper panel: images of Mock or DOCK3
siRNA-transfected cells plated on collagen and
treated with Y27632 for 16 hr. Lower panel: per-
centage of elongated cells after Y27632, H1152,
or blebbistatin treatment (200 cells/experiment,
n = 3, error bars indicate +SE).
(C) Upper panel: percentage of elongated cells af-
ter transfection with four different DOCK3 oligos
(200 cells/experiment, n = 3, error bars indicate
+SE). Lower panel: DOCK3 immunoblot.
(B and C) Student’s t test was used to generate
p values; **p < 0.01, *p < 0.05.
(D) Migration speeds of cells on collagen in 1%
serum treated with H1152 where indicated.
Student’s t test was used to generate p values;
**p < 0.01.
(E) Rac activation (GTP-bound Rac1/total Rac) in
A375M2 cells transfected with siRNAs on colla-
gen. Upper panels: left, representative pulldown;
right, quantification (n = 3, error bars indicate
+SE). Lower panels: A375M2 stably transfected
with DELDOCK3; left, representative pulldown;
right, quantification. (n = 3, error bars indicate
+SE; Student’s t test was used to generate p
values, **p < 0.01, *p < 0.05.)
ment were monitored by time-lapse mi-
croscopy. In this system, cell adhesion
is at least partially dependent on integrin
b1 (Figure S1A available online,) and cells
show similar adhesion to when plated on
a thin, rigid layer of collagen (Figure S1B).
Approximately 90% of A375M2 cells dis-
played a rounded morphology on thick
collagen (Figures 1A and 1B, Movie S1),
and higher magnifications show that any
one time about 20% of the rounded cells
move randomly in an amoeboid fashion with dynamic blebbing
plasma membranes (Movie S2, Figure 2F) with velocities of ap-
proximately 0.1 mm per min. These velocities of amoeboid move-
ment on top of a deformable collagen layer are similar to those
observed in a 3D collagen environment (Figure S1C). About
10% of A375M2 cells show an elongated morphology (Figures
1A and 1B), and of these about 40% are moving in a mesenchy-
mal fashion with long protrusions at speeds similar to amoeboid
cells (Figures 1D and 2F). Treatment with cytochalasin D to block
actin polymerization showed that both amoeboid movement and
elongated, mesenchymal-type movement require actin assem-
bly (data not shown).
To examine the interconvertibility of cell morphologies and
movement, we made time-lapse movies from reconstructions
of confocal sections of cells contained within a 3D collagen ma-
trix (Movie S3). These showed that individual A375M2 cells inter-
convert between a rounded and elongated morphology over
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a 24 hr time period. Examination of other melanoma cell lines on
thick collagen showed that several were like A375M2, consisting
of a majority of rounded cells that move in an amoeboid fashion;
another group had similar proportions of rounded and elongated
cells, whereas a third group consisted of a majority of elongated
cells with mesenchymal-type movement (Figure S1D).
To identify GEFs that regulate cell morphology and movement,
we transfected A375M2 cells with siRNA oligonucleotide du-
plexes (Dharmacon Smart Pools) targeting 83 GEFs for Rho fam-
ily GTPases (Table S1) and monitored them on thick collagen
layers. Silencing of DOCK3/MOCA resulted in almost complete
elimination of cells with an elongated morphology and blocked
the interconversion between amoeboid and mesenchymal
movement (Figures 1A and 1B) without affecting adhesive prop-
erties (Figure S1B, lower panel). We have previously shown that
Figure 2. Rac Regulates the Amoeboid-
Mesenchymal Transition
(A) Left panels: images of A375M2 cells trans-
fected with siRNAs or treated with 50 mM
NSC23766, photographed at 24 hr on collagen.
Right panel: percentage of elongated cells
(200 cells/experiment, n = 3, error bars indicate
+SE); inset, Rac1 immunoblot.
(B) Rac activation on collagen after treatment for
the indicated times with Y27632, H1152, or bleb-
bistatin (blebbis). Left: representative pulldown.
Right: quantification (n = 5, error bars indicate
+SE; Student’s t test was used to generate
p values, **p < 0.01, *p < 0.05).
(C) Percentage of elongated cells after Mock or
Rac1 siRNA transfection at 24 hr after treatment
with vehicle, Y27632, H1152, or blebbistatin (200
cells/experiment, n = 3, error bars indicate +SE).
(A and C) Student’s t test was used to generate
p values; **p < 0.01.
(D) Images of A375P cells on collagen stably trans-
fected with Rac1 T17N, Rac1 shRNA, or control
vectors.
(E) Rac1 and RhoA activation in A375M2 and
A375P cells.
(F) Histogram showing the percentage of moving
cells classified by cell shape on collagen after
transfection with siRNAs and treated with H1152
where indicated (n = 3, error bars indicate +SE;
Student’s t test was used to generate p values,
**p < 0.01, *p <0.05).
(G) A375M2 cells on collagen stably expressing
Rac1Q61L. Upper panel: images. Lower panel:
percentage of elongated cells (200 cells/experi-
ment, n = 3, error bars indicate +SE; Student’s
t test was used to generate p values, **p < 0.01).
(H) Migration speeds of cells on collagen. Stu-
dent’s t test was used to generate p values;
**p <0.01.
treatment of A375M2 cells with low
concentrations of the myosin II ATPase
inhibitor blebbistatin resulting in partial
inhibition of actomyosin contractility
leads to an elongated morphology and
mesenchymal movement (Wilkinson
et al., 2005); therefore, we investigated whether this conversion
requires DOCK3. Furthermore, because Rho-ROCK signaling to
phosphorylation of myosin light chain 2 (MLC2) has been shown
to be a key determinant of actomyosin contractility, we investi-
gated whether inhibition of ROCK led to an elongated morphol-
ogy and whether this was dependent on DOCK3. Figure 1B
shows that treatment with blebbistatin or two different ROCK in-
hibitors (Y27632 and H1152) resulted in conversion to elongated
cells moving in a mesenchymal manner (Movies S6 and S7) and
that this was abrogated by siRNAs targeting DOCK3 (Figure 1B;
Movie S8). These results were confirmed with Dharmacon ‘‘On-
Target Plus’’ oligonucleotides, which use a modified chemistry to
reduce off-target effects and are directed at different sequences
of the gene (Figure 1C). Interestingly, although blebbistatin or
ROCK inhibition increased the proportion of elongated cells, it
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did not affect the speed of migration (Figure 1D). Knockdown of
other GEFs from the DBL or the DOCK families did not affect cell
elongation in response to ROCK inhibition (Figure S2).
DOCK3 has been previously characterized as a GEF for Rac
(Namekata et al., 2004); therefore, we investigated whether the
conversion from amoeboid to mesenchymal movement involved
the activation of Rac. Silencing of DOCK3 expression with two
different oligonucleotides showed that Rac activity in A375M2
is dependent on DOCK3 (Figure 1E). Moreover, expression of
an internal deletion mutant, DELDOCK3 (aa 1062–1393) (Name-
kata et al., 2004), which lacks the DHR2 exchange factor domain
but retains protein-protein interaction domains and could act as
a dominant negative, also decreased Rac activation (Figure 1E,
lower panel) and blocked the conversion of rounded cells to elon-
gated morphology (Figure S3). To determine whether Rac activa-
tion is required for the amoeboid-mesenchymal transition, we
silenced Rac1 by siRNA transfection. Figures 2A and 2C and
Movies S4 and S9 show that silencing of Rac1 abolished elonga-
tion of A375M2 cells. To confirm these results, we used treatment
with compound NSC23766, which blocks Rac1 activation by in-
terfering with complex formation between GEFs and Rac (Gao
et al., 2004) or expression of the interfering Rac mutant
Rac1T17N. NSC23766 treatment reduced the proportion of elon-
gated cells to 1.5%, compared with 8% in control A375M2 cells
(Figure 2A). Because NSC23766 has not been shown to affect
Rac activation mediated by DOCK family members, we showed
that NSC23766 blocks Rac activation after overexpression of
DOCK3 (Figure S4). Only rounded cells were found to express
Rac1T17N after transfection (data not shown). To determine
whether cell elongation after inhibition of actomyosin contractility
or ROCK led to Rac activation, we measured Rac-GTP levels af-
ter treatment with blebbistatin or ROCK inhibitors. Figure 2B
shows that these treatments increase Rac activation. This activa-
tion of Rac is dependent on DOCK3 (data not shown). However,
treatment with ROCK inhibitors or blebbistatin did not increase
the proportion of elongated cells if Rac had been depleted by
siRNA (Figure 2C) or by Rac1T17N transfection (data not shown).
A375M2 was derived from a low metastatic melanoma cell
line, A375P (Clark et al., 2000), that has a more elongated mor-
phology (40% elongated) with fewer blebs than A375M2 cells
(Figure 2D). Interestingly, we could show that A375P cells have
lower levels of Rho-GTP and higher levels of Rac-GTP than do
A375M2 cells (Figure 2E). In A375P cell lines stably expressing
either Rac1T17N or shRNA-Rac1, the proportion of elongated
cells was reduced (Figure 2D). These results show that Rac sig-
naling is required for the elongated/mesenchymal phenotype.
Because amoeboid movement of A375M2 cells is dependent
on ROCK (Sahai and Marshall, 2003) but inhibition of ROCK
leads to Rac-dependent mesenchymal-type movement, we in-
vestigated whether inhibition of ROCK in combination with
blockage of Rac activation would prevent cells from moving.
Figure 2F shows that the combination of ROCK-inhibitor treat-
ment with silencing of either Rac or DOCK3 markedly reduces
cell movement. To determine whether activation of Rac signaling
is sufficient to convert rounded cells to elongated cells, we ex-
pressed a constitutively activated Rac1 Q61L in A375M2 cells;
this resulted in the proportion of elongated cells increasing to
40%, compared to 4% in controls (Figure 2G).Blocking Rac Signaling Suppresses Mesenchymal
Movement and Enhances Amoeboid Movement
These experiments show that activation of Rac by DOCK3 in
A375M2 cells results in an elongated morphology and mesen-
chymal movement but do not address the issue of whether
Rac is required for amoeboid movement. Movie S9 shows that
cells in which Rac has been silenced move solely in an amoeboid
fashion. Time-lapse movies from reconstructions of confocal
sections of A375M2 cells suspended within a collagen matrix
show that blockage of Rac signaling either by siRNA transfection
or treatment with NSCC2376 prevents conversion of rounded,
amoeboid cells to elongated mesenchymal-type movement
(Movies S4 and S5; compare with control cells in Movie S3). Sur-
prisingly, analysis of the speed of cells plated on top of a collagen
matrix showed that rounded cells in which Rac signaling was ab-
lated moved up to 1.7-fold faster (Figure 2H). These results dem-
onstrate that not only is Rac activation by DOCK3 required for an
elongated morphology and mesenchymal movement, but it also
suppresses amoeboid movement.
NEDD9 Complexes with DOCK3 to Regulate Rac Activity
DOCK3 is a member of the DOCK180 family of guanine nucleo-
tide exchange factors, and individual members of the family ac-
tivate either Rac or Cdc42 (Cote and Vuori, 2002). The prototyp-
ical member of this family, DOCK180, is activated via a complex
consisting of the adaptors Crk and p130Cas (Kiyokawa et al.,
1998). We speculated that DOCK3 may complex with a member
of the p130Cas family. Expression studies by Q-PCR showed
that p130Cas and NEDD9/HEF1 but not Efs/Sin were expressed
in A375M2 human melanoma cells. Interestingly, NEDD9 is over-
expressed in 35%–50% of metastatic human melanomas and is
overexpressed and involved in invasion in a mouse model of
metastatic melanoma (Kim et al., 2006). To investigate the roles
of NEDD9 and p130Cas, we examined whether silencing of ex-
pression of p130Cas or NEDD9 caused a similar phenotype to si-
lencing of DOCK3 expression. NEDD9 but not p130Cas ablation
reduced the number of elongated cells after treatment with
ROCK inhibitors (Figure 3A; knockdown in Figure S5A). To
show that NEDD9 is required for Rac activation, we transfected
A375M2 with siRNA oligonucleotides. Figure 3B shows that
silencing NEDD9 expression reduces Rac activity.
To confirm that Rac activation by DOCK3 requires NEDD9, we
overexpressed DOCK3 in HEK293T cells. Figure 3C shows that
overexpression of DOCK3 led to Rac activation that was blocked
by silencing of endogenous NEDD9 (knockdown in Figure S5C).
Similarly, Rac activation by overexpressed NEDD9 was depen-
dent on endogenous DOCK3 (Figure 3C, knockdown in Figure
S5D). These results suggest that DOCK3 functions together
with NEDD9 to activate Rac. Therefore, we used coimmunopre-
cipitation to look for evidence that NEDD9 and DOCK3 are in
a signaling complex. We were able to detect an endogenous
complex of DOCK3 with NEDD9 in A375M2 cells (Figure 3D).
These results were confirmed by overexpression analysis; en-
dogenous DOCK3 was found in immunoprecipitates isolated
with Flag-tag antibodies from cells expressing Flag-epitope-
tagged NEDD9 (Figure 3D, lower-left panel), whereas endoge-
nous NEDD9 could be detected in complexes with HADOCK3 af-
ter expression of an HA-epitope-tagged DOCK3 (Figure 3D).Cell 135, 510–523, October 31, 2008 ª2008 Elsevier Inc. 513
Rac Signaling Suppresses Actomyosin Contractility
through WAVE2
Because amoeboid movement is associated with elevated
levels of MLC2 phosphorylation and actomyosin contractility,
we investigated whether Rac acts by controlling actomyosin
contractility. Reduction of Rac1 expression with Rac1 siRNA in
A375M2 cells (Figure 4A) or Rac1 shRNA in A375P cells
(Figure 4B) increased phosphorylation of MLC2 on threonine18
and serine19. Similarly, silencing of DOCK3 or NEDD9 led to in-
creased MLC2 phosphorylation (Figures 4C and 4D). Con-
versely, expression of constitutively activated Rac1Q61L in
A375M2 cells that leads to an elongated morphology resulted
in reduced levels of MLC2 phosphorylation (data not shown).
Figure 3. NEDD9Complexeswith DOCK3 to
Regulate Rac Activity
(A) Upper panel: images of siRNA-transfected
A375M2 cells on collagen treated with Y27632
for 16 hr. Lower panel: percentage of elongated
cells (200 cells/experiment, n = 3, error bars indi-
cate +SE; Student’s t test was used to generate
p values, **p < 0.01). The scale bar represents
100 mm.
(B) Rac1 activation on collagen of siRNA-trans-
fected A37M2 cells. Left panel: representative
pulldown and NEDD9 immunoblot. Right panel:
quantification of pulldowns (n = 3, error bars indi-
cate +SE).
(C) Rac1 activation in 293T cells transfected with
HADOCK3 or FlagNEDD9 and siRNAs plated on
plastic. Upper panels: representative pulldowns
and immunoblots. Lower panels: quantification
of pulldowns (n = 3, error bars indicate +SE).
(B and C) Student’s t test was used to generate
p values; **p < 0.01, *p < 0.05.
(D) Upper-left panel: anti-NEDD9 immunoprecipi-
tates immunoblotted for DOCK3. Lower-left panel:
anti-Flag immunoprecipitates from A375M2 cells
transfected with Flag-NEDD9 immunoblotted for
DOCK3. Upper-right panel: anti-HA immunopre-
cipitates from A375M2 cells transfected with HA-
DOCK3 immunoblotted for NEDD9. Lower-right
panel: anti-NEDD9 immunoprecipitates from
A375M2 cells transfected with HA-DOCK3 immu-
noblotted for HA-DOCK3. IP, immunoprecipitated.
These results show that Rac negatively
regulates MLC2 phosphorylation and
thereby actomyosin contractility.
To find the Rac effector responsible for
regulating MLC2 phosphorylation, we
used siRNAs targeting the Rac effectors
PAK1, 2, 3, and 4 as well as WAVE1, 2,
and 3; only WAVE2 depletion led to ele-
vated levels of MLC2 phosphorylation
(Figure 4E). Consistent with its role in
Rac-dependent Arp2/3 promotion of ac-
tin assembly and the formation of cell
protrusions characteristic of the mesen-
chymal type of cell movement (Leng
et al., 2005), WAVE2 silencing reduced
the proportion of elongated A375M2 cells on thick collagen
(data not shown) and abolished Rac-dependent elongation after
ROCK inhibition (Figure 4F). We were not able to detect any de-
fect in elongation after ROCK inhibition or change in the levels of
MLC2 phosphorylation when depleting WAVE1 or WAVE3
(Figure S6).
To confirm the results obtained for WAVE2, we used individual
Dharmacon On-Target Plus oligos targeting different regions of
WAVE2. As shown in Figure 4G, there is a strong correlation be-
tween the degree of knockdown for WAVE2 protein and the re-
duction in the percentage of elongated cells after ROCK-inhibitor
treatment. These results therefore show that elongation of
A375M2 cells requires Rac signaling to WAVE2 and that
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WAVE2 negatively regulates MLC2 phosphorylation, thereby
suppressing rounded morphology and amoeboid movement.
ROCK Signaling Downregulates Rac Activity via
ARHGAP22
We have shown that Rac opposes amoeboid movement while in-
hibition of ROCK in amoeboid cells leads to Rac activation, sug-
gesting that ROCK signaling in rounded, amoeboid cells sup-
presses Rac activation. A potential mechanism is through
ROCK regulation of a Rac GAP (Ohta et al., 2006). We investi-
gated whether a Rac GAP regulates the mesenchymal transition
by screening an siRNA library consisting of 72 Rho family GAPs
(Table S2). Silencing of ARHGAP22 led to elongation of A375M2
rounded cells (Figures 5A and 5B, kd in Figure S5B) without alter-
ing the adhesion properties of the cells (Figure S1B, lower panel).
Figure 4. Rac Suppression of Amoeboid
Movement Is Mediated by WAVE2
(A) Phospho-MLC (p-T18/S19-MLC2) in A375M2
cells on collagen after transfection with Rac1
siRNA (n = 3, error bars indicate +SE). Inset: repre-
sentative immunoblot.
(B) Phospho-MLC in A375P cells on collagen sta-
bly transfected with Rac1 shRNA (n = 3, error bars
indicate +SE). Inset: representative immunoblot.
(C) Phospho-MLC in A375M2 cells on collagen
after transfection with siRNAs. Left panel: repre-
sentative immunoblot. Right panel: quantification
(n = 3, error bars indicate +SE).
(D) Phospho-MLC in A375M2 cells on collagen af-
ter transfection with NEDD9 siRNAs. Upper panel:
representative immunoblot. Lower panel: quantifi-
cation (n = 3, error bars indicate +SE).
(E) Phospho-MLC in A375M2 cells on collagen af-
ter transfection with WAVE2 siRNA. Upper panel:
representative immunoblot. Lower panel: quantifi-
cation (n = 3, error bars indicate +SE).
(F) Mock or WAVE2 siRNA-transfected A375M2
cells on collagen treated with Y27632, H1152, or
blebbistatin for 24 hr. Left panel: images of cells.
Right panel: histogram showing the percentage
of elongated cells (200 cells/experiment, n = 3,
error bars indicate +SE).
(G) Left panel: percentage of elongated A375M2
cells on collagen after transfection with four differ-
ent On Target siRNAs against WAVE2 and treated
with Y27632 (200 cells/experiment, n = 3, error
bars indicate + SE). Right panel: WAVE2 immuno-
blot.
Student’s t test was used to generate p values;
**p < 0.01, *p < 0.05.
We did not observe this increase in the
number of elongated cells when knocking
down the expression of GAPs belonging
to the same subfamily such as ARH-
GAP24 or ARHGAP25 or other GAPs
(Figure S7).
To show that ARHGAP22 regulates
Rac-GTP levels, we assayed Rac activity
in A375M2 cells in which expression of
ARHGAP22 was abrogated with two different sets of oligonucle-
otides. RacGTP levels were increased 2-fold when ARHGAP22
expression was silenced (Figure 5C). Silencing of ARHGAP22
led to decreased MLC2 phosphorylation (Figure 5D), consistent
with our observations that the Rac-WAVE2 pathway downregu-
lates MLC phosphorylation. Silencing of a subset of other Rac
GAPs did not affect Rac activity (Figure S7C).
To demonstrate that ROCK regulates ARHGAP22, we used
A375P cells expressing a ROCK-estrogen receptor fusion pro-
tein to provide a system whereby ROCK activity could be con-
trolled (Croft and Olson, 2006). Activation of ROCK-ER-WT
(wild-type) by 16 hr treatment with tamoxifen led to cells acquir-
ing a rounded morphology with associated blebbing similar to
A375M2 cells (Figure S8) and a substantial decrease in the level
of Rac-GTP (Figure 5E, kd in Figure S5E). This decrease was
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not observed if cells were depleted of ARHGAP22 by siRNA
(Figure 5E). In contrast, tamoxifen treatment of cells expressing
a kinase-inactive version of ROCK fused to ER (kinase-dead
K121G) did not lead to significant changes in Rac activation
or cell morphology (Figure S8). These experiments show that
ROCK suppresses Rac activation through ARHGAP22.
A375M2 cells have high levels of actomyosin contractility
driven by ROCK, and because treatment with low doses of
the myosin II inhibitor blebbistatin leads to the activation of
Rac (Figure 2B), we investigated whether ROCK signals to
ARHGAP22 via actomyosin contractility. Blebbistatin treatment
blocked the fall in Rac-GTP levels stimulated by increased
ROCK activity, suggesting that ROCK does not regulate
ARHGAP22 directly but does so via modulating actomyosin
contractility (Figure 5F).
Figure 5. ROCK Signaling Downregulates
Rac via ARHGAP22
(A) Images of Mock or ARHGAP22 siRNA-trans-
fected A375M2 cells plated on collagen for 24 hr.
(B) Percentage of elongated cells (200 cells/exper-
iment, n = 3, error bars indicate +SE; Student’s
t test was used to generate p values, **p < 0.01,
*p < 0.05).
(C) Rac activation in ARHGAP22 siRNA-trans-
fected cells on collagen. Upper panels: represen-
tative pulldown. Lower panel: quantification
(n = 3, error bars indicate +SE; Student’s t test
was used to generate p values, *p < 0.05).
(D) Phospho-MLC in ARHGAP22 siRNA-trans-
fected A375M2 cells on collagen. Upper panel:
representative immunoblot. Lower panel: quantifi-
cation (n = 3, error bars indicate +SE; Student’s
t test was used to generate p values, **p < 0.01).
(E) Rac activation in A375P-ROCKER cell lines
(wild-type [WT] or kinase dead [KD]) transfected
with siRNAs plated on plastic and treated with
4-OH-tamoxifen or vehicle for 16 hr. Left panels:
representative pulldowns. Right panels: quantifi-
cation (n = 5, error bars indicate +SE).
(F) Rac activation in A375P-ROCKERWT cells
treated with 4-OH-tamoxifen and blebbistatin
where indicated for 16 hr. Upper panel: represen-
tative pulldown. Lower panel: quantification (n = 3,
error bars indicate +SE.
(E and F) Student’s t test was used to generate
p values, **p < 0.01, *p < 0.05.
(G) Percentage of elongated cells on collagen at
24 hr from A375M2 cells transfected with siRNAs
against ARHGAP22, DOCK3, or both, (200 cells/
experiment, n = 3, error bars indicate +SE; Stu-
dent’s t test was used to generate p values, **p <
0.01, *p < 0.05). Inset: immunoblot for DOCK3.
Taken together, our data show that the
Rac GEF DOCK3 activates Rac to pro-
mote an elongated, mesenchymal-type
phenotype, whereas ROCK signaling to
the Rac GAP ARHGAP22 opposes this
phenotype. Consistent with this model,
we find that silencing of ARHGAP22,
which results in increased number of
elongated cells, could be overcome by simultaneous silencing
of DOCK3 (Figure 5G, kd in Figure S5F). These results confirm
that DOCK3 and ARHGAP22 act in opposite ways to regulate
the mesenchymal-amoeboid transition.
Roles of NEDD9, DOCK3, and ARHGAP22 in 3D Cell
Movement
To examine the roles of the NEDD9-DOCK3-Rac and ROCK-
ARHGAP22 signaling pathways in 3D cell movement, we tested
invasion into a 3D collagen I matrix. We used two cell lines,
A375M2 and WM1361, in the presence of serum or IGF1,
a known motility factor for melanoma cells produced by dermal
fibroblasts (Neudauer and McCarthy, 2003). Knockdown of
NEDD9, DOCK3, or Rac1 alone or inhibition of ROCK had little
effect on the numbers of invading cells (Figure 6A, kd in
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Figure S5G). However, imaging of invaded cells showed that al-
though control A375M2 cells consisted of 10% elongated and
90% rounded cells (Figures 6B and 6C), like cells plated on
top of a thick collagen layer (Figures 1A and 1B), abrogation
of NEDD9, DOCK3, or Rac expression reduced the proportion
of invaded elongated cells (Figures 6B and 6C). In contrast, ab-
rogation of ARHGAP22 expression markedly increased the pro-
portion of invaded elongated cells (Figures 6B and 6C). These
results show that when the NEDD9-DOCK3-Rac pathway is
blocked, cells invade through amoeboid movement, whereas
when ROCK-ARHGAP22 signaling is blocked, cells invade in
a mesenchymal fashion. These results suggest that cells use ei-
ther amoeboid or mesenchymal-type movement to invade a 3D
collagen matrix. Therefore, we tested whether blocking compo-
nents of both signaling pathways would reduce invasion. The
combination of H1152 to block ROCK signaling with NEDD9,
DOCK3, or Rac1 ablation led to a significant decrease in inva-
sion (Figure 6A), showing that amoeboid and mesenchymal
modes of movement can act redundantly for invasion into
a 3D matrix.
To investigate how signaling through these pathways influ-
ences cell morphology in vivo, we imaged subcutaneous tumors
from A375M2 and WM1361 cells expressing green fluorescent
protein (GFP). In the cortical regions, we found similar propor-
tions of rounded and elongated cells to when cells were plated
on a thick layer of collagen I (Figure 7A and Figure S1D). Imaging
of tumors derived from a shARHGAP22-GFP-A375M2 stable cell
line showed that the proportion of elongated cells was increased
(Figure 7A), consistent with the effects of ARHGAP22 silencing in
culture.
To examine cell movement in vivo, we used two-photon in-
travital microscopy. As previously shown (Pinner and Sahai,
Figure 6. Roles of NEDD9, DOCK3, and
ARHGAP22 in 3D Cell Movement
(A) Invasion into collagen I matrix of A375M2 or
WM1361 cells transfected with siRNAs and
treated with H1152 where indicated (n = 4, error
bars indicate +SE; Student’s t test was used to
generate p values, **p < 0.01, *p < 0.05).
(B) Images of invaded GFP-A375M2 cells trans-
fected with siRNAs after 24 hr of collagen I inva-
sion assay. The scale bar represents 50 mm.
(C) Morphology of cells invading the matrix ex-
pressed as the percentage of elongated cells
(n = 6, error bars indicate +SE; Student’s t test
was used to generate p values, **p < 0.01).
2008), control A375M2 cells show a
range of cell behaviors, including fast
amoeboid movement with rapidly chang-
ing morphology; slower, more chaotic
movement with blebbing morphology;
and extending protrusions with mesen-
chymal morphology. Figure 7B panels ii
and iv and Movie S10 show that in the
cortical regions of the tumor, fast amoe-
boid movement into the matrix is ob-
served, whereas in the inner regions of the tumor, cells move
between each other mainly through elongated, mesenchymal-
type movement. Movies S11 and S12 show the two types of
motility in more detail. Speeds of amoeboid movement in vivo
are approximately 30 times faster than in culture (Figure 7B,
lower panel), reflecting the lack of persistence of movement
in culture due to the absence of chemotactic gradients. Similar
to our observations in culture (Figures 1B, 1D, and 2F), treat-
ment with ROCK inhibitor Y37652 reduced amoeboid move-
ment and led to a 2.5-fold increase in the number of cells mov-
ing in an elongated, mesenchymal manner within the tumor
(Figure 7C).
During metastasis, cell motility is required for extravasation
and colonization of new tissues. To determine how Rac activity
influenced these processes, we made use of an assay that com-
pares the ability of control or siRNA-transfected cells injected
into the tail vein to colonize the lung (Pinner and Sahai, 2008).
A feature of this short-term assay is that it permits evaluation
of cytoskeletal events important for attachment to blood vessels,
survival, and lung colonization (Tsuji et al., 2006) while ruling out
effects on proliferation that may obscure other effects. Two
hours after tail vein injection, tumor cells are lodged in capillaries
with a morphology corresponding to the shape of the blood ves-
sels (Pinner and Sahai, 2008). We chose WM1361 cells for these
experiments because preliminary experiments show they are
more efficient than A375M2 in entering the lung in this assay,
and the higher proportion of elongated cells (Figure S1D) makes
it easier to evaluate the contribution of the DOCK3-Rac pathway.
Equal numbers of control and Rac1- or DOCK3-depleted
WM1361 cells, marked with different-colored fluorescent pro-
teins, were mixed and injected into the tail vein of mice. Thirty
minutes after injection, there were equal numbers of control
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Figure 7. Roles of DOCK3 and ARHGAP22 In Vivo
(A) Left panels: Representative images of the tumor surface from GFP-A375M2sh control or shARHGAP22 cells, and histogram of the percentage of elongated/
rounded cells (n = 4, error bars indicate +SE; Student’s t test was used to generate p values, *p < 0.05). Right panels: representative images of tumor surface from
GFP-WM1361 cells, and histogram of the percentage of elongated/rounded cells (n = 4, error bars indicate +SE).
518 Cell 135, 510–523, October 31, 2008 ª2008 Elsevier Inc.
and siRNA-depleted WM1361 cells lodged in the narrow vessels
of the lungs (Figure 7D). However, after 6 hr, the number of Rac1-
or DOCK3-depleted cells that had entered the lung parenchyma
was approximately 1.4 times more than control cells. Because
depletion of Rac or DOCK3 enhances amoeboid movement,
these results show that a rounded morphology and amoeboid
movement favors colonization, whereas elevated Rac activity
compromises the ability of cells to colonize the lung. These
observations are consistent with studies showing that reduction
in amoeboid movement and acquisition of an elongated mor-
phology through abrogation of PDK1 expression reduces the
ability of tumor cells to colonize the lung (Pinner and Sahai,
2008).
Expression Levels of NEDD9, DOCK3, and ARHGAP22
Determine the Amoeboid-Mesenchymal Transition
To extend our observations, we examined a set of melanoma cell
lines for the expression of DOCK3, ARHGAP22, and NEDD9 to-
gether with an assessment of their morphology. When plated on
a thick layer of collagen I, cell lines WM1361, SKMEL2, and
SBCL2 contain 30%–65% elongated cells (Figure 8A and
Figure S1D). These cell lines express NEDD9, DOCK3, and ARH-
GAP22, and when ROCK was inhibited, the proportion of cells
with elongated morphology increased (Figure 8A, Figures S1D
and S10). CHL, SKMEL28, and 501MEL cell lines show a high
proportion of elongated cells and have little ARHGAP22, and
treatment with ROCK inhibitor produced no change in the pro-
portion of elongated cells. In contrast, WM3670, WM3629, and
WM1366 show a high proportion of cells with rounded morphol-
ogy and express ARHGAP22 (Figure 8A and Figure S9A). Inhibi-
tion of ROCK in these cell lines increased the proportion of elon-
gated cells, apart from WM1366, where presumably the very
high levels of ARHGAP22 keep Rac inactive even when ROCK
is inhibited. We classified the cell lines into three categories ac-
cording to their appearance on collagen: elongated (E), more
than 65% elongated/mesenchymal cells, little change with
ROCK-inhibitor treatment; rounded/amoeboid (R), less than
20% elongated/mesenchymal cells, increase in the percentage
of elongated cells with ROCK-inhibitor treatment; and mixed
(M), 30%–65% elongated cells, increase in the percentage of
elongated cells with ROCK-inhibitor treatment. We compared
Rac activation levels in selected cell lines; SKMEL28 (E group)
displayed the highest Rac activity levels, whereas M group cells
(WM1361, SBCL2, and A375P) had moderate levels of Rac1 ac-
tivity. Finally, WM3670 and A375M2 (both R) showed the lowest
levels of Rac activity (Figure S9B).
Silencing of ARHGAP22 expression in WM1361(M),
SKMEL2(M), SBCL2(M), and WM3670(A) led to an increase inthe proportion of elongated cells (Figures 8B and 8C, kd in
Figure S5H), whereas silencing of NEDD9 or DOCK3 reduced
the proportion of elongated cells (Figures 8B and 8C, kd in
Figure S5H). In contrast, overexpression of NEDD9 in SKMEL2
or WM1361 cell lines resulted in a significant increase in the num-
ber of elongated cells (Figure S11). In CHL and SKMEL28 cell
lines with a very high proportion of elongated cells, silencing of
NEDD9 or DOCK3 expression resulted in conversion to
a rounded morphology (Figures 8B and 8C). These results with
a panel of cell lines suggest that NEDD9, ARHGAP22, and
DOCK3 are key regulators of the morphology and mode of cell
movement in melanomas and that their expression levels to-
gether with the signaling pathways that control their activity
determine cell morphology and movement.
DISCUSSION
DOCK3 belongs to the DOCK180 family of GEFs and was iden-
tified as a presenilin-binding protein specifically expressed in
neurons (Cote and Vuori, 2002; Kashiwa et al., 2000; Namekata
et al., 2002). DOCK3 activates Rac1 (Namekata et al., 2004)
and has been shown to colocalize with actin filaments at
growth cones, suggesting that it is involved in cytoskeletal re-
organization by locally regulating Rac activity. We show that
DOCK3 is expressed in melanoma cells and is required for
Rac-driven mesenchymal-type cell motility, whereas it re-
presses amoeboid movement via activation of Rac1. Recent
work from Palamidessi et al. (2008) has demonstrated the im-
portance of Rab5-dependent endocytic traffic in the activation
of Rac for mesenchymal-type movement; whether DOCK3 is
localized in endosomes remains to be determined. Although
multiple Rac GEFs are expressed in A375M2 cells, in our
screen of 83 Rho family GEFs, DOCK3 was the only Rac GEF
whose silencing suppressed mesenchymal movement. For ex-
ample, silencing of DOCK180, a well-characterized Rac activa-
tor expressed in melanoma cells, appeared to have no effect on
cell morphology or movement. Although we are cautious in in-
terpretation of negative results, our data suggest that GEFs
provide specificity in signaling to Rac activation to control cell
movement.
We show that DOCK3 is in a complex with NEDD9, a member
of the p130Cas family, and they act together in Rac activation.
NEDD9 has recently been established as a melanoma metasta-
sis gene that is overexpressed in metastatic melanomas and en-
hances invasion in vitro and metastasis of normal and trans-
formed melanocytes (Kim et al., 2006). Our data argue that
a key role of NEDD9 in metastasis is in Rac activation. Members
of the p130Cas family are adaptor proteins that mediate integrin(B) Multiphoton intravital microscopy of GFPMLC-A375M2 subcutaneous tumors. Panels i and ii: tumor matrix interface. Panels iii and iv: images from within the
tumor. Panels ii and iv are merged images of three consecutive time points colored red, green, and blue to highlight motile cells by spatial separation (arrows);
white pixels indicate stationary objects. Scale bars represent 25 mm. Lower panel: box and whisker plot of cell migration speeds.
(C) Upper panel: histogram of control and ROCK inhibitor Y27632-treated cells showing different types of motile behavior into matrix surrounding tumor or be-
tween cells within tumor (error bars indicate +SE; n = 10 for control mice, and n = 5 for Y27632-treated mice). Chi-square test shows that Y27632 treatment
changes the proportions of moving cells within the categories; p < 0.001. Lower panel: scatter plot of the number of cell movement events per 7 mm optical slice
classified by type of cell motility. Mann Whitney U test shows that Y27632 treatment increases the number of moving elongated cells; p = 0.0001.
(D) Representative images of mouse lungs injected with GFP-mock-transfected WM1361 cells or mRFP-siRNA-transfected cells at 30 min or 6 hr after injection.
Scale bars represent 50 mm. Bar charts: relative proportions of mock- and siRNA-transfected cells within the lungs (error bars indicate +SE, n = 8 in each case;
Student’s t test was used to generate p values, **p < 0.01).Cell 135, 510–523, October 31, 2008 ª2008 Elsevier Inc. 519
Figure 8. Expression levels of NEDD9, DOCK3, and ARHGAP22 Determine Cell Morphology in Melanoma Cell Lines
(A) Relative expression levels of NEDD9, DOCK3, ARHGAP22, cell shape, and effects of ROCK inhibitor. Plasticity is the effect of ROCK inhibition on the per-
centage of elongated cells; , no effect; +, 1.5-fold; ++, 3-fold; +++ 5- to 10-fold increase in the percentage of elongated cells.
(B) Images of cell lines transfected with siRNAs and plated on collagen. The scale bar represents 100 mm.
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signaling and are linked to Rac activation through a Cas-Crk-
DOCK180 complex (O’Neill et al., 2000). Interestingly, Kim
et al. (2006) did not find a role for p130Cas in melanoma cell mi-
gration, consistent with our finding that abrogation of DOCK180
or p130Cas expression had no effect on cell morphology or mo-
tility of A375M2 cells.
An important finding from our studies is that Rac signaling re-
presses amoeboid movement. Abrogation of Rac activity leads
to elevated phosphorylation of MLC2 and faster amoeboid
movement. Rac promotes cell protrusions and lamellipodia
characteristic of mesenchymal movement through the SCAR/
WAVE2 complex. SCAR/WAVE2 is a member of the WASP fam-
ily of proteins that activates Arp2/3 a group of seven proteins
that control actin assembly (Higgs and Pollard, 2001; Welch,
1999). Interestingly, we find that Rac-dependent suppression
of MLC2 phosphorylation requires WAVE2, suggesting a tight
interplay between the mechanism that promotes Rac-depen-
dent actin rearrangements in mesenchymal movement and
the suppression of amoeboid movement. Signaling complexes
containing WASP family members recruit regulatory proteins
for Rho family GTPases, raising the possibility that Rac and
Rho activity may be coordinated by GAP and GEF activities lo-
cated in the multiprotein complexes that regulate actin assem-
bly (Soderling et al., 2002). Interestingly, Hem-1, a haemopoetic
specific partner of WAVE2, has been described to interact with
two different Rho GAPs, and with the catalytic subunit and the
MYPT1 targeting subunit of myosin phosphatase (Weiner et al.,
2006), all of which could function to downregulate MLC2 phos-
phorylation.
Rac promotes mesenchymal-type movement and suppresses
amoeboid movement by keeping MLC2 phosphorylation low. Our
data show that Rac activity is controlled by the interplay between
the NEDD9-DOCK3 and ROCK-ARHGAP22 pathways (Fig-
ure 8D). In amoeboid movement, ROCK signaling promotes
high levels of actomyosin contractility to provide the force for
movement (Wyckoff et al., 2006), and the activation of
ARHGAP22 prevents Rac activation from suppressing amoeboid
movement. A negative regulatory role for Rho/ROCK signaling
toward Rac has been described many times, and a recent study
identified FILGAP as a Rac GAP phosphorylated and activated
by ROCK (Ohta et al., 2006). Interestingly, ARHGAP22 is closely
related to FILGAP, but although we can show that the GAP activity
of ARHGAP22 depends on ROCK activity and actomyosin con-
tractility, we have been unable to find evidence of ROCK-medi-
ated phosphorylation of ARHGAP22 (V.S.M., unpublished data).
A striking finding from our studies is the observation that Rac
and Rho have opposing effects on different modes of tumor cell
motility and that changing the activity of one signaling pathway
changes the mode of movement (Figure 8D). These observa-
tions reinforce the view that different modes of cell movement
are interconvertible (De Wever et al., 2004; Wolf et al., 2003).
We hypothesize that efficient metastasis may need each form
of movement depending on the cellular microenvironment.Amoeboid movement can be a rapid form of movement where
the composition of the extracellular matrix allows the contractile
force of the cell to deform the matrix (Wyckoff et al., 2006; Wolf
et al., 2003), whereas mesenchymal movement may be required
in more rigid environments where proteolysis is needed to gen-
erate tracks for the cell to move (Friedl, 2004). Within A375M2
tumors, cell movement is mesenchymal and unaffected by
ROCK inhibition. We find that Rac activity associated with mes-
enchymal movement inhibits lung colonization by circulating tu-
mor cells, consistent with the observations of Pinner and Sahai
(2008) that rounded morphology and amoeboid movement favor
lung colonization. Another aspect of high levels of actomyosin
contractility and rounded morphology is that it may protect tu-
mor cells from shear stresses in the circulation (Wang et al.,
2002; Sahai et al., 2007).
Histopathological studies show that the tumor cells in malig-
nant melanoma show morphological variability, appearing
rounded/epithelioid or spindle shaped (Rosai, 2004). The varia-
tion in expression levels of NEDD9, DOCK3, and ARHGAP22
that we have identified are likely to be important determinants
of the ability of tumor cells to convert between these different
morphologies and associated modes of movement. Through
these signaling pathways, tumor cells may switch between
mesenchymal and amoeboid types of movement, allowing
metastatic tumor cells to adapt their morphology and move-




Antibodies were as follows: Rho A (sc-418), ERa (sc-543) and DOCK180 (sc-
13163) from Santa Cruz; anti-Cas and Purified IgG from Transduction Labora-
tories; diphospho-Thr18/Ser19-MLC2 from Cell Signaling Technology; MLC2
and a-tubulin from Sigma; WAVE2 from BD; Flag M2 from Stratagene;
NEDD9 (2G9) from AbCam; HA (MMS-101) from Covance; and Rac1 (23A8)
from Upstate. Anti-DOCK3 was a kind gift from Dr. David Schubert (Salk Insti-
tute, La Jolla, CA). Y-27632 (Tocris, Southampton, UK), blebbistatin, H1152,
and NSC23766 (Calbiochem, Merck Biosciences, Nottingham, UK) were
also used.
Cell Culture, Transfection, and Plasmids
A375P and A375M2 cells were from R. Hynes (Howard Hughes Medical Insti-
tute, Massachusetts Institute of Technology). CHL, SKMEL2, SKEML28,
SBCL2, WM1361, WM1366, WM3629, WM3670, and 501MEL were from
Drs. I Arozarena and R Marais (Institute of Cancer Research, London). Cells
were maintained in Dulbecco’s modified Eagle’s medium (DMEM) or RPMI
containing 10% fetal calf serum. Plasmid transfections were performed with
Amaxa Nucleofector and reagents (Amaxa, GmbH). Stable cell lines were se-
lected with G418 at 100 mg/ml (Sigma). Y27632 was used at 10 mM, H1152 at
5 mM, blebbistatin at 2.5 mM, and NSC23766 at 50 mM. CB6-EGFP-RacQ61L
and CB6-EGFP-Rac1T17N were from Dr. Michael Way (Cancer Research
UK, London Research Institute). EGFP-N1 was from Clontech (Basingstoke,
UK). Sure Silencing shRNA plasmids Rac1 (KH00733N), DOCK3
(KH07467G), and ARHGAP22 (KH20417N) were from Superarray. pCIneo
DOCK3HA was from Dr. Hideo Kimura (National Institute of Neuroscience,(C) Histogram of the percentage of elongated cells from two elongated (E), three mixed (M), and two rounded/amoeboid (R) melanoma cell lines transfected with
Mock, DOCK3, NEDD9, or ARHGAP22 siRNAs and seeded on collagen (200 cells/experiment, n = 3, error bars indicate +SE; Student’s t test was used to gen-
erate p values, ** p< 0.01, *p < 0.05).
(D) Diagram outlining the relationships between signaling pathways, cell morphology, and movement.
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Tokyo, Japan). LZRSpBMN-Z-delta-NEDD9 was from Dr. Linda Chin (Dana
Farber Cancer Institute, MA).
Cell Culture on Thick Layers of Collagen
Fibrillar bovine dermal collagen was prepared at a 1.7 mg/ml dilution in DMEM
according to the manufacturer’s protocol (Cohesion); 300 ml was placed in
wells of 24-well plates, and 700 ml was placed in wells of 12-well plates. Cells
were seeded on top of collagen in medium containing 10% serum and allowed
to adhere for 24 hr, and medium was changed to 1% serum for 16 hr. Except
where indicated, all cell imaging, immunoblotting, and pulldown assays were
performed on cells cultured on a thick layer of collagen.
siRNA Transfections
siRNA oligonucleotides from Dharmacon (Lafayette, USA) are listed in Tables
S1 and S2, and sequences are in Table S3. Cells (2 3 105) were plated in
a 60 mm dish and transfected the next day with 20 nM SmartPools or individual
oligos, with Optimem-I and Hiperfect (QIAGEN, Renfrewshire, UK). Cells were
plated on collagen in 1% fetal bovine serum 48 hr after transfection and ana-
lyzed 24 hr later.
Time-Lapse Phase-Contrast Microscopy
Multisite microscopy of cells in 12-well plates containing thick layers of colla-
gen was performed in a humidified CO2 chamber with a Diaphot inverted mi-
croscope (Nikon, UK) with a motorized stage (Prior Scientific, UK) controlled by
Simple PCI software (Compix). For evaluation of the percentage of elongated
cells, a cell was considered elongated when its longest dimension was twice
the shortest and when it showed at least one protrusion.
Time-Lapse Confocal Fluorescent Microscopy
A375M2 membrane-targeted -GFP cells were mixed with a collagen matrix
and plated in MatTek (Ashland, MA,) glass-bottomed dishes and placed on
a Tokai heated stage.
Tracking Assays
Tracking of cell migration within collagen matrices was performed as de-
scribed (Wilkinson et al., 2005) over a period of 24 hr from 16 hr after the gel
was set. Individual cells were tracked in a semiautomated manner by repeated
random selection of cells in movie frames and manual tracing of migration
pathways with Simple PCI software. Speeds are presented as ‘‘box and whis-
ker’’ plots showing median, quartile, and highest and lowest values. Any cells
moving through convection were excluded.
Quantitative Real-Time One-Step PCR
The Quantitect SYBR Green RT-PCR system was used according to the man-
ufacturer’s instructions.
Immunoprecipitation and Immunoblotting
Lysates were fractionated by SDS-PAGE and transferred to nitrocellulose fil-
ters. Western blotting was performed with the ECL Plus detection System
(GE Healthcare) with horseradish peroxidase-conjugated secondary anti-
bodies (Sigma). Immunoprecipitations were performed as described (Sanz-
Moreno et al., 2003). For p-Thr18/Ser19-MLC2 detection, whole-cell extracts
from cells on collagen were harvested in Laemmli sample buffer and sonicated
for 15 s prior to centrifugation.
Pulldown Assays
Glutathione S-transferase (GST)-conjugated Rhotekin and PAK-CRIB were
expressed from pGEX-Rhotekin and pGEX-CRIB, and assays performed as
in (Sahai and Marshall, 2002). Except where indicated, extracts were derived
from cells on a thick collagen matrix (3 ml collagen/6-well dish).
Tumor Imaging
Nude mice were injected subcutaneously with either sh control or shRNA sta-
bly transfected A375M2 cells expressing GFP or WM1361 expressing GFP.
When tumors were 3–7 mm in diameter, mice were anaesthetized and imaged
as described (Wyckoff et al., 2006). For in vivo imaging of cell movement, ten
control and five Y27632-treated tumors were imaged; four different regions522 Cell 135, 510–523, October 31, 2008 ª2008 Elsevier Inc.were imaged for 20 min for each tumor. Moving cells were defined as those
that moved 10 mm or more during 20 min.
Lung Extravasation Assay
WM1361 cells stably expressing membrane-tethered GFP or mRFP were
transfected with Mock or siRNAs. Forty-eight hours after transfection, cells
were trypsinized, mixed in equal numbers, and injected into the tail vein of
nude mice. Mice were sacrificed after 30 min or 6 hr, and lungs were examined
for GFP- or mRFP-expressing cells.
Invasion Assays
Cells were suspended in serum-free collagen I at 2.3 mg/ml to a final concen-
tration of 23 103 cells/100 ml. One hundred microliter aliquots were dispensed
into 96-well ViewPlates (Perkin-Elmer) coated with bovine serum albumin.
Plates were centrifuged at 3003 g and incubated at 37C/10% CO2 for 30 min
before insulin growth factor or fetal calf serum to 5% was added with H1152
where indicated. After 24 hr incubation, cells were fixed in formaldehyde (final
concentration 4%) and stained with 5 mg/ml Hoechst 33258 (Molecular
Probes-Invitrogen). Confocal Z slices were collected from each well at 50 mm
and 3 mm (bottom of well) with an INCELL3000 high-content microscope. Nu-
clear staining was quantified with INCELL3000 software with the Object Inten-
sity module. Samples were run in quadruplicate and averaged. The invasion
index was calculated as number of cells at 50 mm divided by the total number
of cells. Data are presented as percentage of the invasion index of mock-trans-
fected cells. For the 3D imaging of invaded cells, sequential Z sections of em-
bedded cells were obtained by indirect immunofluorescence microscopy with
a Nikon C1 confocal microscope. 3D reconstructions of embedded cells in-
vading into the collagen were made with Volocity software (Improvision Inc,
Waltham, MA,). For evaluation of the percentage of elongated cells invading,
a cell was considered elongated when its longest dimension was twice the
shortest and when it showed at least one protrusion.
Statistical Analysis
Student’s t test was performed in all quantifications of Rac activation, P-MLC,
percentage of elongated/mesenchymal-type cells, migration speed, invasive
index, percentage of knockdown, and lung extravasation assay. ** indicates
p < 0.01, and * indicates p < 0.05. For the scatter plot in Figure 7C, Mann Whit-
ney U test was used. Error bars indicate +SE.
SUPPLEMENTAL DATA
Supplemental Data include Supplemental Experimental Procedures, three
tables, 11 figures, and 12 movies and can be found with this article online at
http://www.cell.com/supplemental/S0092-8674(08)01236-1.
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